Faron Pharmaceuticals - Innovatiivisia lääketieteen ratkaisuja (Osa 2)

[RipaRapa]

@Clark_kent

Let’s say in Finnish that the responses to bex+aza are on par with aza alone when treating study patients.

Lest there be a misunderstanding, this interpretation is false concerning the TP53 mutation. Furthermore, your interpretation only applies to HR MDS wt patients. In addition, your interpretation focuses on CR.